Literature DB >> 6206569

Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I).

H Mitsuya, H G Guo, J Cossman, M Megson, M S Reitz, S Broder.   

Abstract

Tetanus-toxoid specific helper-inducer T-cell clones, which had been infected and transformed by human T-cell leukemia-lymphoma virus (HTLV-I), were obtained from an antigen-specific human T cell line by using a limiting dilution technique in the presence of the virus. These HTLV-I-infected T-cell clones proliferated specifically in response to soluble tetanus toxoid but, unlike normal T cells, they could do so in the absence of accessory cells. The HTLV-I-infected T-cell clones did not present the antigen to autologous antigen-specific T cells that were not infected with HTLV-I. The capacity of helper-inducer T cells to retain antigen-specific reactivity after infection by HTLV-I, while losing the normal T-cell requirement for accessory cells, has clinical and theoretical implications.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206569     DOI: 10.1126/science.6206569

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  17 in total

1.  Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I.

Authors:  S Matsushita; M Robert-Guroff; J Trepel; J Cossman; H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

2.  Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men.

Authors:  K Krohn; W G Robey; S Putney; L Arthur; P Nara; P Fischinger; R C Gallo; F Wong-Staal; A Ranki
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

Review 3.  Interactions of viruses with the immune system.

Authors:  C A Mims
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

Review 4.  Mechanisms of T-cell activation by human T-cell lymphotropic virus type I.

Authors:  P Höllsberg
Journal:  Microbiol Mol Biol Rev       Date:  1999-06       Impact factor: 11.056

5.  Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I.

Authors:  S Matsushita; H Mitsuya; M S Reitz; S Broder
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

6.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

7.  Alterations in cytotoxic and helper T cell function after infection of T cell clones with human T cell leukemia virus, type I.

Authors:  R Yarchoan; H G Guo; M Reitz; A Maluish; H Mitsuya; S Broder
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

8.  Transformation of human T-cell clones by Herpesvirus saimiri: intact antigen recognition by autonomously growing myelin basic protein-specific T cells.

Authors:  F Weber; E Meinl; K Drexler; A Czlonkowska; S Huber; H Fickenscher; I Müller-Fleckenstein; B Fleckenstein; H Wekerle; R Hohlfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

9.  Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.

Authors:  A Ranki; S H Weiss; S L Valle; J Antonen; K J Krohn
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

10.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.